| 1.5 -0.01 (-0.66%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.06 | 1-year : | 2.26 |
| Resists | First : | 1.76 | Second : | 1.94 |
| Pivot price | 1.71 |
|||
| Supports | First : | 1.49 | Second : | 1.23 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 1.71 |
| MA(100) : | 1.54 |
MA(250) : | 1.75 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 3 |
D(3) : | 9.3 |
| RSI | RSI(14): 40.3  |
|||
| 52-week | High : | 2.4 | Low : | 1.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DYAI ] has closed above bottom band by 11.6%. Bollinger Bands are 108.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.48 - 1.5 | 1.5 - 1.51 |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Tue, 16 Apr 2024
Exploring Stock Surges: Key Insights, Noteworthy BUZZ: KAVL, PRSO, DYAI, WISA, JAGX | FinancialContent Business ... - Financial Content
Sun, 31 Mar 2024
Dyadic International Full Year 2023 Earnings: Misses Expectations - Simply Wall St
Thu, 28 Mar 2024
Dyadic Announces Change in Board and Management Leadership Roles - GlobeNewswire
Thu, 28 Mar 2024
Dyadic Reports 2023 Full Year Results and Recent Company Progress - GlobeNewswire
Thu, 28 Mar 2024
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK - WICZ
Thu, 28 Mar 2024
Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 30.8 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 181 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | -234.5 % |
| Operating Margin | -315.9 % |
| Return on Assets (ttm) | -46.7 % |
| Return on Equity (ttm) | -80.2 % |
| Qtrly Rev. Growth | -7.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -6.25 |
| PEG Ratio | 0 |
| Price to Book value | 7.5 |
| Price to Sales | 14.98 |
| Price to Cash Flow | -6.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|